Anaesthetic drugs & techniques
Sugammadex aliquot pilot project in adults having elective surgical procedures – A pharmacoeconomic retrospective deidentified chart review to improve quality and cost of anesthesia care
Authors' conclusion
Aliquoting and dosing sugammadex guided by quantitative neuromuscular monitoring in this single center reduces annual drug acquisition costs and produces consistent savings across dose ranges.
Study context
- Population
- Adults having elective surgical procedures requiring GA, single centre
- Participants
- 524 adults
- Exposure
- Sugammadex aliquoting guided by quantitative neuromuscular monitoring vs subjectively determined routine full-vial antagonism of NMB
- Sugammadex aliquotsn = 258
- Neostigmine/glycopyrrolaten = 111
- No pharmacological reversaln = 63
- Outcome
- Cost of NMB antagonism per case (gross drug cost and net cost including quantitative monitoring)
Methodological detailspharmacoeconomic analysis, single-centre, deidentified
- Pharmacoeconomic analysis
- Single-centre
- Deidentified
Main finding
As reported in the abstract
Mean cost per case, all patients
| Group | Value | Net cost (including monitoring) |
|---|---|---|
| Sugammadex aliquots | mean $51.50 | $71.66 |
| Full-vial | mean $129.05 | $149.21 |
Value
Sugammadex aliquotsmean $51.50
Full-vialmean $129.05
Net cost (including monitoring)
Sugammadex aliquots$71.66
Full-vial$149.21
- Total hospital net savings with aliquoting (including quantitative monitoring)
- $20,008
Observational data: associations, not effects.
Further findings
| Outcome | Neostigmine/glycopyrrolate | No pharmacological reversal |
|---|---|---|
| Mean gross cost per case by reversal strategy | mean $4.39/case | |
| Savings of 200-mg sugammadex vial | — not stated in the abstract | $129.05 |
— not stated in the abstract
Mean gross cost per case by reversal strategy
- No drug costs without pharmacological reversal
Original publication
Sugammadex aliquot pilot project in adults having elective surgical procedures – A pharmacoeconomic retrospective deidentified chart review to improve quality and cost of anesthesia care. J Clin Anesth. Published 30 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →